Abbott’s HUMIRA® (Adalimumab) Meets Primary Endpoints in Phase III Ulcerative Colitis Study

Press Release

Abbott’s ® (Adalimumab) Meets Primary Endpoints in Phase III Study

May 10, 2011

Abbott Park, Illinois (NYSE: ABT) — Abbott’s HUMIRA® (adalimumab) met its primary endpoint of clinical in a Phase III study of with moderate to severe ulcerative colitis. Results were presented at the (DDW) scientific conference in Chicago.

Ulcerative colitis (UC) is a that causes and ulceration in the lining of the colon or large intestine. It is estimated that approximately 700,000 people in the United States have UC. Symptoms include , rectal bleeding, increased and .

Reads Full Abbott’s HUMIRA® (Adalimumab) Meets Primary Endpoints in Phase III Ulcerative Colitis Study Press Release

Leave a Reply